- In patients with chronic kidney disease and Hepatitis C virus infection, sofosbuvir-based direct-acting antiviral therapy was safe and effective.
- Patients with stage 3 kidney disease who were cured of infection experienced an improvement in their kidney function following treatment.
Hepatitis C virus infection, the most frequent chronic viral infection in the United States, is a common comorbidity in patients with chronic kidney disease.
Newswise — Washington, DC (September 7, 2017) — A new study indicates that direct-acting antiviral therapy is safe and effective in patients with chronic kidney disease (CKD) and Hepatitis C virus (HCV) infection. The study, which appears in an upcoming issue of the Clinical Journal of the American Society of Nephrology (CJASN), also found that treatment may help improve some patients’ kidney function.
HCV infection—which often causes liver disease—is common in patients with CKD, and it increases their risk of progressing to kidney failure. Sofosbuvir is a potent direct-acting antiviral therapy against HCV, but concerns about potential kidney toxicity have been raised, particularly in patients with CKD.
To determine the safety and efficacy of sofosbuvir in patients with CKD, Meghan Sise, MD, MS (Massachusetts General Hospital) and her colleagues studied 98 patients with stages 1-3 CKD who received sofosbuvir-based therapy in a large healthcare system.
Overall sustained virologic response (which is synonymous with cure of HCV infection) was 81%, and average kidney function while on the treatment was stable. Patients with more advanced CKD were more likely to be cured of HCV infection than those with mild CKD. In addition, patients with advanced CKD who were cured of HCV infection experienced an improvement in their kidney function following treatment. Sofosbuvir was reasonably well tolerated: adverse events were common (81%), but serious adverse events (17%) and treatment discontinuations (8%) were uncommon. Also, there was no detectable effect of the degree of CKD on the rate of adverse events.
Larger studies are needed to determine if eradication of HCV with direct-acting antiviral therapy slows or prevents progression to end stage kidney disease in patients with CKD and HCV.
“The use of direct-acting antiviral therapy in patients with Hepatitis C infection has transformed the illness into a curable one. This study shows that these medications can be safely and effectively used in patients with stage 1-3 kidney disease,” said Dr. Sise.
In an accompanying editorial, Richard Johnson, MD (University of Colorado) and Michiko Shimada, MD, PhD (Hirosaki University Graduate School of Medicine, in Japan) noted that there are other antiviral drugs that are effective in patients with CKD and HCV, and unlike sofosbuvir, they are not eliminated by the kidneys. Therefore, additional research on the effects of different antivirals in patients with compromised kidney function are needed. “We predict that HCV, like hepatitis B virus and HIV, will slowly disappear as a major medical problem for patients with renal disease,” they wrote.
Study co-authors include Elke Backman, PharmD, Guillermo Ortiz, MD, Gregory Hundemer, MD, Nneka Ufere, MD, Donald Chute, BA, Joseph Brancale, BA, Dihua Xu, PhD, Jessica Wisocky, NP, Ming Lin, MD, Arthur Kim, MD, Ravi Thadhani, MD, MPH, and Raymond Chung, MD.
MES – research grant funding from Gilead Sciences, Abbvie, Merck. Scientific advisory board participant, Abbvie and Merck
JW - Scientific advisory board participant, Gilead
AK – Scientific advisory board participant, Bristol Myers Squibb
RT – Scientific advisory board participant, Merck
RC – Research grants to the institution: Gilead Sciences, Abbvie, Merck, Bristol-Myers Squibb, Janssen.
The article, entitled “Effect of Sofosbuvir-based Hepatitis C Virus Therapy on Kidney Function in Patients with Chronic Kidney Disease,” will appear online at http://cjasn.asnjournals.org/ on September 7, 2017, doi: 10.2215/CJN.02510317.
The editorial, entitled “Contemporary Management of Hepatitis C in Patients with CKD,” will appear online at http://cjasn.asnjournals.org/ on September 7, 2017.
The content of this article does not reflect the views or opinions of The American Society of Nephrology (ASN). Responsibility for the information and views expressed therein lies entirely with the author(s). ASN does not offer medical advice. All content in ASN publications is for informational purposes only, and is not intended to cover all possible uses, directions, precautions, drug interactions, or adverse effects. This content should not be used during a medical emergency or for the diagnosis or treatment of any medical condition. Please consult your doctor or other qualified health care provider if you have any questions about a medical condition, or before taking any drug, changing your diet or commencing or discontinuing any course of treatment. Do not ignore or delay obtaining professional medical advice because of information accessed through ASN. Call 911 or your doctor for all medical emergencies.
Since 1966, ASN has been leading the fight to prevent, treat, and cure kidney diseases throughout the world by educating health professionals and scientists, advancing research and innovation, communicating new knowledge, and advocating for the highest quality care for patients. ASN has nearly 17,000 members representing 112 countries. For more information, please visit www.asn-online.org or contact the society at 202-640-4660.
# # #